Abadie Wesley M, Partington Erin J, Fowler Craig B, Schmalbach Cecelia E
Department of Otolaryngology, Mike O'Callaghan Federal Medical Center, Nellis AFB, Nevada, USA.
Division of Otolaryngology, University of Alabama-Birmingham, Birmingham, Alabama, USA
Otolaryngol Head Neck Surg. 2015 Oct;153(4):504-11. doi: 10.1177/0194599815586779. Epub 2015 Jun 4.
Proliferative verrucous leukoplakia (PVL) is a rare and recalcitrant form of leukoplakia. The purpose of this review is to further characterize the risk factors, clinical course, and optimal treatment for this highly aggressive, premalignant lesion.
Twenty-six articles on PVL with a total of 329 PVL cases.
A systematic review of the literature using Ovid, PubMed, Cochrane Database, and gray literature was conducted of all PVL cases reported between 1985 and 2014. Inclusion criteria required reporting of patient follow-up and recurrence rates. Data were analyzed using descriptive statistics. Student t test and Fisher exact test were used to identify factors associated with malignant transformation.
The mean patient age was 63.9 years. Most patients were female (66.9%) and nontobacco users (65.22%). Mean follow-up was 7.4 years, with an average of 9.0 biopsies per patient during this period. Proliferative verrucous leukoplakia exhibited histopathologic features along a progressive spectrum, evolving from leukoplakia to verrucous hyperplasia and ultimately invasive carcinoma. Surgery was the most common treatment implemented, but recurrence rates among 222 patients reached 71.2%. Subgroup analysis of 277 patients identified a 63.9% malignant transformation rate, and 39.6% of patients died of their disease. Age, sex, and tobacco use were not identified as risk factors associated with progression to cancer.
Proliferative verrucous leukoplakia is a rare form of leukoplakia with a high rate of malignant transformation. It necessitates high clinical suspicion, to include a lifetime of close follow-up and repeat biopsies by a health care provider well versed in oral carcinoma.
增殖性疣状白斑(PVL)是一种罕见且难治的白斑形式。本综述的目的是进一步明确这种高度侵袭性的癌前病变的危险因素、临床病程及最佳治疗方法。
26篇关于PVL的文章,共329例PVL病例。
对1985年至2014年期间报道的所有PVL病例,使用Ovid、PubMed、Cochrane数据库及灰色文献进行系统的文献综述。纳入标准要求报告患者随访情况及复发率。采用描述性统计分析数据。使用学生t检验和Fisher精确检验来确定与恶性转化相关的因素。
患者平均年龄为63.9岁。大多数患者为女性(66.9%)且不吸烟(65.22%)。平均随访时间为7.4年,在此期间每位患者平均活检9.0次。增殖性疣状白斑呈现出一系列渐进性的组织病理学特征,从白斑发展为疣状增生,最终发展为浸润性癌。手术是最常用的治疗方法,但222例患者的复发率达到71.2%。对277例患者的亚组分析显示恶性转化率为63.9%,39.6%的患者死于该病。年龄、性别和吸烟未被确定为与癌症进展相关的危险因素。
增殖性疣状白斑是一种罕见的白斑形式,恶性转化率高。需要高度的临床怀疑,包括终身密切随访以及由精通口腔癌的医疗保健人员进行重复活检。